- Home
- MTDR vs LEGN Comparison
MTDR vs LEGN Comparison
Compare MTDR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTDR
- LEGN
- Stock Information
- Founded
- MTDR 2003
- LEGN 2014
- Country
- MTDR United States
- LEGN United States
- Employees
- MTDR N/A
- LEGN N/A
- Industry
- MTDR Oil & Gas Production
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- MTDR Energy
- LEGN Health Care
- Exchange
- MTDR Nasdaq
- LEGN Nasdaq
- Market Cap
- MTDR 7.0B
- LEGN 7.0B
- IPO Year
- MTDR 2012
- LEGN 2020
- Fundamental
- Price
- MTDR $53.10
- LEGN $39.70
- Analyst Decision
- MTDR Strong Buy
- LEGN Strong Buy
- Analyst Count
- MTDR 14
- LEGN 12
- Target Price
- MTDR $75.43
- LEGN $79.50
- AVG Volume (30 Days)
- MTDR 1.0M
- LEGN 976.3K
- Earning Date
- MTDR 02-18-2025
- LEGN 03-10-2025
- Dividend Yield
- MTDR 1.81%
- LEGN N/A
- EPS Growth
- MTDR 1.28
- LEGN N/A
- EPS
- MTDR 7.14
- LEGN N/A
- Revenue
- MTDR $3,478,958,000.00
- LEGN $520,183,000.00
- Revenue This Year
- MTDR $33.76
- LEGN $121.13
- Revenue Next Year
- MTDR $20.99
- LEGN $65.25
- P/E Ratio
- MTDR $7.44
- LEGN N/A
- Revenue Growth
- MTDR 32.92
- LEGN 122.96
- 52 Week Low
- MTDR $47.15
- LEGN $30.17
- 52 Week High
- MTDR $71.08
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- MTDR 32.29
- LEGN 64.82
- Support Level
- MTDR $55.88
- LEGN $34.36
- Resistance Level
- MTDR $59.22
- LEGN $36.39
- Average True Range (ATR)
- MTDR 2.05
- LEGN 1.67
- MACD
- MTDR -0.46
- LEGN 0.34
- Stochastic Oscillator
- MTDR 6.27
- LEGN 94.68
About MTDR Matador Resources Company
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.